Skip to main
  1. Stocks
  2. Orchestra BioMed Holdings Inc
  3. Forecast
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Hldgs is attractive because its AVIM therapy and Virtue SAB programs target large, underserved cardiovascular markets with differentiated, partner-led commercialization that can scale without heavy internal sales infrastructure. The BACKBEAT pivotal study has completed enrollment of 349 randomized patients, the FDA has confirmed the PMA supplement route, and management expects primary endpoint data in May 2027 with a potential U.S. launch in 1H28, supporting a credible path to near-term value creation. Financially, the company ended September 2026 with $101.9 million in cash and investments, raised about $80.5 million net in November 2026, and expects its capital to fund operations through 2028, reducing funding risk while development advances.

Bears say

Orchestra BioMed Hldgs is exposed to substantial regulatory and execution risk because neither BackBeat CNT nor VirtueSAB can be commercialized without FDA PMA or CE certification, and the company acknowledges that pivotal trials may take longer and cost more than expected while still failing to prove safety or efficacy. Its reliance on licensing and distribution partners also weakens the outlook, since commercialization depends on third parties that may be unable or unwilling to support market penetration, while any collaboration can be terminated and the company may lack the resources to go it alone. Competitive pressure is intense, with larger rivals such as Boston Scientific, Abbott, BIOTRONIK, Medtronic, Becton Dickinson, and B Braun possessing far greater financial, manufacturing, marketing, and technical resources, and its patent position may not be strong enough to prevent costly infringement disputes.

OBIO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

OBIO Analyst Forecast & Price Prediction

Get the latest OBIO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OBIO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 7 analysts, OBIO has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


OBIO Analyst Forecast & Price Prediction

Get the latest OBIO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OBIO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OBIO stock data and trends